Nonetheless, early CD8+ T cell infiltration in PRAD and persistence of potential DCs in late-stage NEPC in this model suggest that deeper analysis may be informative in addressing the disappointing clinical results seen with conventional immune checkpoint blockade therapy in prostate cancer. This evidence concerns the gene CD8A and prostate adenocarcinoma.